Innocan Pharma Corp. Stock
€0.23
Your prediction
Financial data and news for Innocan Pharma Corp.
sharewise wants to provide you with the best news and tools for Innocan Pharma Corp., so we directly link to the best financial data sources.
Financials
News
Innocan Pharma to participate in the White Label World Expo on February 27-28th, 2024
Herzliya, Israel and Calgary, Alberta - (February 20, 2024) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), is pleased to announce that CEO Iris
Innocan Pharma Reports Q3 2023 Results Including US$3.334M Increase in Revenues Compared to Q3, 2022
- US$4.083M Revenues for Q3 2023 compared to US$749,000 for Q3 2022, representing an increase of 445%
- US$3.664M Gross Profit for Q3 2023 compared to USD 715,000 for Q3
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
Herzliya, Israel and Calgary, Alberta - May 09, 2024 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
With its submission of a Pre-IND Meeting Request Letter, Innocan initiates the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its prolonged CBD
Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M
Herzliya, Israel and Calgary, Alberta – April 1, 2024 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), a pharmaceutical technology company
Innocan Pharma paves its way to LPT-CBD Chemistry, Manufacturing and Controls (CMC), key milestones for FDA approval.
Herzliya, Israel and Calgary, Alberta - March 25, 2024 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the development of drug
Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of Approximately C$2 Million
NOT FOR DISSEMINATION IN OR INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
HERZLIYA, Israel and CALGARY, Alberta – March 15, 2024 – Innocan Pharma Corporation (the “
Innocan Pharma’s LPT-CBD Has the Potential to Support a new Therapeutic Venue for Neurological Disorders According to Recent Study
Innocan Announces Notice of Intention to Complete a Private Placement of Units
Herzliya, Israel and Calgary, Alberta – March 5, 2024 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4)
Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits
Herzliya, Israel and Calgary, Alberta – February 26, 2023 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and
Innocan Provides Corporate Update & Preliminary Q4 and Fiscal Year 2023 Financial Highlights
Herzliya, Israel and Calgary, Alberta - (February 13, 2024) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), is pleased to provide the
Innocan Pharma to provide a corporate update via Zoom livestream on February 12, 2024, at 4:00pm EST
Herzliya, Israel and Calgary, Alberta - (February 5, 2024) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce that it will provide a
Innocan Pharma Announces Expert Team for LPT CBD Application to United States Food and Drug Administration
Herzliya, Israel and Calgary, Alberta (December 12, 2023) Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pioneer in the pharmaceutical and